Onpattro (Patisiran) for Amyloidosis | MyAmyloidosisTeam

Connect with others who understand.

sign up Log in
Resources
About MyAmyloidosisTeam
Powered By

Overview
Onpattro is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with nerve damage resulting from hereditary transthyretin-mediated (hATTR) amyloidosis. Onpattro is also referred to by its drug name, patisiran.

Onpattro is a member of a class of drugs called small interfering ribonucleic acids (siRNA). Onpattro is believed to work by interfering with the creation of amyloid proteins in cells.

How do I take it?
Prescribing information states that Onpattro is given as an intravenous infusion (slow injection into a vein) by a health care professional. Onpattro is usually given in a health clinic or doctor’s office. It should be administered according to the frequency specified by the physician.

Side effects
The FDA-approved label for Onpattro lists common side effects as upper respiratory tract infections and infusion reactions that include back, neck, or other muscle pain; flushing; nausea; abdominal pain; difficulty breathing or cough; chest discomfort or pain; headache; rash; chills; dizziness; fatigue; increased heart rate or palpitations; hypotension (low blood pressure) or hypertension (high blood pressure); and facial edema (swelling).

A serious side effect listed for Onpattro is vitamin A deficiency.

For more details about this treatment, visit:
Onpattro — Alnylam
Onpattro — Alnylam Assist

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in